Diachrome
This article was originally published in The Tan Sheet
Executive Summary
CVS will be the first retailer to offer Nutrition 21's Diachrome nutrient-based insulin sensitizer for type 2 diabetes, the firm announces Feb. 22. "We believe Diachrome is a very promising product that addresses a healthcare crisis in the United States and worldwide and has significant market potential," Nutrition 21 COO Paul Intlekofer said, noting that the results of a 447-subject study on the safety and efficacy of Diachrome are to be published this summer. In addition, an economic analysis by Thomas Jefferson University shows that widespread use of Diachrome "could deliver significant health care savings" in the U.S. Efficacy and cost savings should encourage healthcare stakeholders to incorporate Diachrome into their treatment protocols." The move to CVS expands the firm's mass market presence: in January, Rite-Aid became the first retailer to carry the chromium picolinate supplement Chromax (1"The Tan Sheet" Jan. 23, 2006, In Brief)...
You may also be interested in...
Nutrition 21 Expands Into Cardiovascular Area With Iceland Health Buy
Nutrition 21 strengthens its focus on finished products and gains entry to the omega-3 market with the purchase of fish oil importer and manufacturer Iceland Health
Chromax hits retail stores
Rite Aid will be the first mass retailer to carry Nutrition 21's Chromaxchromium picolinate dietary supplement, marking the brand's debut in retail stores, the firm announces Jan. 13. "The Rite Aid commitment is a significant initial step in our transition from primarily a wholesale ingredients supplier to also a supplier of branded finished goods," Nutrition 21 COO Paul Intlekofer said. As a result, the firm expects to see positive financial results by the second half of 2006. Public awareness of the supplement's insulin-related benefits is increasing, the exec claimed, citing a recent Newsweek article naming the brand as a "Super Nutrient," as well as a New York Times series on diabetes and insulin. The firm plans to support its marketing strategy for retail sale with a comprehensive marketing and communications program...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.